Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials

Diederichsen "Natural history of subclinical atrial fibrillation detected by implanted loop recorders" J Am Coll Cardiol (2019) 10.1016/j.jacc.2019.09.050

[4]

Vitolo "Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis" Eur J Intern Med (2021) 10.1016/j.ejim.2021.05.038

[5]

Mahajan "Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis" Eur Heart J (2018) 10.1093/eurheartj/ehx731

[6]

Toennis "The influence of atrial high-rate episodes on stroke and cardiovascular death: an update" Europace (2023) 10.1093/europace/euad166

[7]

Gage "Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation" JAMA (2001) 10.1001/jama.285.22.2864

[8]

Lip "Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project" Stroke (2015) 10.1161/strokeaha.114.007199

[9]

Ng "Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial" Age Ageing (2016) 10.1093/ageing/afv156

[10]

Lip "Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms" Thromb Haemost (2022) 10.1055/a-1467-2993

[11]

Romiti "Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III" Thromb Haemost (2022) 10.1055/s-0042-1756355

[12]

Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis [published online ahead of print July 3, 2023]. Thromb Haemost. https://doi.org/10.1055/s-0043-1770724. 10.1055/s-0043-1770724

[13]

Kirchhof "Anticoagulation with edoxaban in patients with atrial high-rate episodes" N Engl J Med (2023) 10.1056/nejmoa2303062

[14]

Healey "Apixaban for stroke prevention in subclinical atrial fibrillation" N Engl J Med (2024) 10.1056/nejmoa2310234

[15]

McIntyre "Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials" Circulation (2024) 10.1161/circulationaha.123.067512

[16]

Lee "Incorporating lag time to benefit into prevention decisions for older adults" JAMA (2013) 10.1001/jama.2013.282612

[17]

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher, Alessandro Liberati, Jennifer Tetzlaff et al.

Annals of Internal Medicine 2009 10.7326/0003-4819-151-4-200908180-00135

[18]

Schulman "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients" J Thromb Haemost (2010) 10.1111/j.1538-7836.2009.03678.x

[19]

Liu "IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves" BMC Med Res Methodol (2021) 10.1186/s12874-021-01308-8

[20]

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al.

BMJ 2011 10.1136/bmj.d5928

[21]

Lopes "Apixaban versus aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA" J Am Coll Cardiol (2024) 10.1016/j.jacc.2024.05.002

[22]

Okumura "Low-dose edoxaban in very elderly patients with atrial fibrillation" N Engl J Med (2020) 10.1056/nejmoa2012883

[23]

Connolly "Apixaban in patients with atrial fibrillation" N Engl J Med (2011) 10.1056/nejmoa1007432

[24]

Uittenbogaart "Burden of atrial high-rate episodes and risk of stroke: a systematic review" Europace (2018) 10.1093/europace/eux356

[25]

Siegal "What we have learned about direct oral anticoagulant reversal" Hematology Am Soc Hematol Educ Program (2019) 10.1182/hematology.2019000072

[26]

Chai-Adisaksopha "Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials" J Thromb Haemost (2015) 10.1111/jth.13139

[27]

Fang "Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants" Stroke (2012) 10.1161/strokeaha.111.630731

[28]

Patel "Subclinical atrial fibrillation and anticoagulation: weighing the absolute risks and benefits" Circulation (2024) 10.1161/circulationaha.123.067919

[29]

Svennberg "What lies beneath the surface—treatment of subclinical atrial fibrillation" N Engl J Med (2024) 10.1056/nejme2311558

[30]

Singer "The net clinical benefit of warfarin anticoagulation in atrial fibrillation" Ann Intern Med (2009) 10.7326/0003-4819-151-5-200909010-00003

[31]

Polymeris "Oral anticoagulants in the oldest old with recent stroke and atrial fibrillation" Ann Neurol (2022) 10.1002/ana.26267

[32]

Lip "Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?" Eur Heart J (2013) 10.1093/eurheartj/ehs435

[33]

Zhang "Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis" Eur J Epidemiol (2021) 10.1007/s10654-021-00751-7

[34]

Fauchier "Causes of death and influencing factors in patients with atrial fibrillation" Am J Med (2016) 10.1016/j.amjmed.2016.06.045

[35]

Marijon "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study" Circulation (2013) 10.1161/circulationaha.112.000491

[36]

Vinter "Temporal trends in lifetime risks of atrial fibrillation and its complications between 2000 and 2022: Danish, nationwide, population based cohort study" BMJ (2024)

[37]

Chao "2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary" Thromb Haemost (2022) 10.1055/s-0041-1739411

[38]

Romiti "Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial" Thromb Haemost (2023) 10.1055/s-0043-1769612

[39]

Romiti "Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients" Thromb Haemost (2022) 10.1055/a-1515-9630

Metrics

7

Citations

39

References

Details

Published: Dec 01, 2024
Vol/Issue: 21(12)
Pages: 2422-2428
License: View

Authors

King Abdulaziz City for Science and Technology (KACST) – Oxford Centre of Excellence in Petrochemicals (KOPRC), Inorganic Chemistry Laboratory, Department of Chemistry, University of Oxford; Oxford OX1 3QR; UK

Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Thomas Dr, Liverpool L14 3PE ,; Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Fredrik Bajers Vej 7K, 9220 Aalborg Øst, Aalborg ,

Q

Qing Yang

University of North Texas

X

Xin Zhou

Shihezi University

Funding

National Natural Science Foundation of China Award: 82270349

National Aerospace Science Foundation of China Award: 82320108001

Project for Key Medicine Discipline Construction of Guangzhou Municipality Award: TJYXZDXK-069C

Cite This Article

Chuanyi Huang, Wennan Liu, Yiwen Fang, et al. (2024). Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials. Heart Rhythm, 21(12), 2422-2428. https://doi.org/10.1016/j.hrthm.2024.06.038

Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: A pooled analysis of the NOAH-AFNET 6 and ARTESiA trials

You May Also Like